Core Insights - Argo Biopharma and Novartis have upgraded their collaboration in cardiovascular treatments, granting Novartis rights to two early-stage molecules outside of China for treating severe hypertriglyceridemia and mixed dyslipidemia, along with priority negotiation rights for BW-00112 (ANGPTL3) [1] - The total potential value of the collaboration between Argo Biopharma and Novartis has exceeded $9.3 billion, reflecting a deepening partnership in the siRNA and cardiovascular treatment fields [3] - The global RNAi (RNA interference) market is rapidly expanding, with a projected market size of $25.195 billion by 2030, driven by the increasing application of siRNA therapies in chronic diseases [7] Company Developments - Argo Biopharma, established in April 2021, focuses on siRNA drug development and has previously signed exclusive licensing agreements with Novartis worth up to $4.165 billion [3] - Novartis has been strategically investing in siRNA therapies, including the acquisition of The Medicines Co. for $9.7 billion, which provided access to Inclisiran, a long-acting lipid-lowering drug [4] - Recent collaborations, such as with Arrowhead Pharmaceuticals, highlight Novartis's commitment to expanding its siRNA portfolio, with potential milestone payments reaching $2 billion [5] Industry Trends - The RNAi therapy market has seen significant growth, with a compound annual growth rate (CAGR) of 449.2% from 2018 to 2020, indicating strong future potential [7] - Chinese companies are increasingly participating in the global siRNA market, with notable collaborations and licensing agreements emerging, reflecting a shift in the landscape [8] - Despite the promising advancements in siRNA technology, challenges remain, including delivery mechanisms and potential side effects, necessitating ongoing research and development [8][11]